We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A bipartisan group of senators continues to push for legislation that would ban most pay-for-delay agreements between brand and generic drugmakers, going far beyond restrictions outlined in a landmark Supreme Court decision handed down last month.